We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Device Products » 510(k) Change Analysis – Webinar Recording/Transcript

Other Options

USB Audio Recording/Transcript - Aug. 22, 2019

$287.00

USB Audio Recording/Transcript - Aug. 22, 2019

$258.00

USB Audio Recording/Transcript - Aug. 22, 2019

$244.00

USB Audio Recording/Transcript - Aug. 22, 2019

$230.00

USB Audio Recording/Transcript - Aug. 22, 2019

$215.00

510(k) Change Analysis – Webinar Recording/Transcript

$287.00
Device Products

Product Details

510(k) Change Analysis: Make the Guidance Documents Work for You

The FDA’s 510(k) design change guidance documents are not the easiest to understand and incorporate. While the guidance’s flowcharts were designed to help guide evaluation and decision-making, they can instead be confusing. This presentation will provide you with a clear understanding of the decision paths and processes presented in the guidance documents, the information you need to write a solid SOP and the tools for effective implementation — helping you to stand up to an inspection.

Presentation Takeaways:

Industry expert Dan O’Leary, President of Ombu Enterprises, LLC, will present information on the guidance documents, including:

  • The role of risk management (ISO 14971:2007) in the evaluation process
  • The decision-making process embodied in the flowcharts
  • The criteria behind the flowchart decision boxes
  • How to keep quality records that support your decision

 

Bonus material! You’ll receive an Excel workbook, that implements the logic in the flowcharts, guiding you through the decision-making process and enabling you to provide sufficient documentation.

This presentation will show you how to develop a well-reasoned decision-making process and appropriate documentation to help avoid a 483.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing